0001564590-21-040826.txt : 20210804 0001564590-21-040826.hdr.sgml : 20210804 20210804161552 ACCESSION NUMBER: 0001564590-21-040826 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210804 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210804 DATE AS OF CHANGE: 20210804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 211144209 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 8-K 1 adpt-8k_20210804.htm 8-K adpt-8k_20210804.htm
false 0001478320 0001478320 2021-08-04 2021-08-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2021

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Washington

001-38957

27-0907024

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

1551 Eastlake Avenue East, Suite 200,

Seattle, Washington

 

98102

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

ADPT

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 


 

 

Item 2.02

Results of Operations and Financial Condition.

 

On August 4, 2021, Adaptive Biotechnologies Corporation (the “Company”) issued a press release regarding the Company’s financial results for the quarter ended June 30, 2021. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

 

Description

99.1

 

Press Release dated August 4, 2021

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Adaptive Biotechnologies Corporation

 

 

 

 

Date: August 4, 2021

 

By:

/s/ Chad Cohen

 

 

 

Chad Cohen

 

 

 

Chief Financial Officer

 

 

 

EX-99.1 2 adpt-ex991_6.htm EX-99.1 adpt-ex991_6.htm

EXHIBIT 99.1

Adaptive Biotechnologies Reports Second Quarter 2021 Financial Results

 

 

SEATTLE, Aug. 4, 2021 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2021.

 

“We had another strong quarter with 83% revenue growth over prior year,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “I am encouraged by our performance across the business and excited about the emerging data from our immune medicine platform, which we expect to monetize for multiple opportunities in research, diagnostics and drug discovery.”

Recent Highlights

 

Revenue of $38.5 million for the second quarter 2021, representing an 83% increase from the second quarter 2020

 

clonoSEQ clinical sequencing volume in the second quarter 2021 grew 75% versus prior year and 15% over the first quarter of 2021

 

Signed a license agreement with Vaccibody to leverage Adaptive Biotechnologies’ T-cell data to inform the development of a T-cell based SARS-CoV-2 vaccine

 

Signed an agreement with Moderna to use immunoSEQ T-MAP COVID to measure the T-cell response to their second generation COVID vaccine and their Zika vaccine

 

Published case control data in Lyme disease and completing enrollment in ImmuneSense study to enable T-Detect Lyme offering in our CLIA certified lab around year end

 

Advanced T-Detect pipeline in autoimmune diseases including Crohn’s and Ulcerative Colitis for IBD differential diagnosis, and generated new early signal in Multiple Sclerosis

Second Quarter 2021 Financial Results

Revenue was $38.5 million for the quarter ended June 30, 2021, representing an 83% increase from the second quarter in the prior year. Sequencing revenue was $18.6 million for the quarter, representing a 132% increase from the second quarter in the prior year. Development revenue was $20.0 million for the quarter, representing a 53% increase from the second quarter in the prior year.

Operating expenses were $88.3 million for the second quarter of 2021, compared to $57.9 million in the second quarter of the prior year, representing an increase of 53%.

Net loss was $49.3 million for the second quarter of 2021, compared to $33.5 million for the same period in 2020.

Adjusted EBITDA (non-GAAP) was a loss of $35.6 million for the second quarter of 2021, compared to a loss of $28.5 million for the second quarter of the prior year.

Cash, cash equivalents and marketable securities was $689.5 million as of June 30, 2021.


2021 Financial Guidance

Adaptive Biotechnologies expects full year 2021 revenue to be in the range of $148 million to $155 million, representing 54% growth at the mid-point of the range over full year 2020 revenue. This compares to Adaptive Biotechnologies’ previous outlook of $145 million to $155 million.

Webcast and Conference Call Information

Adaptive Biotechnologies will host a conference call to discuss its second quarter 2021 financial results after market close on Wednesday, August 4, 2021 at 4:30 PM Eastern Time. The conference call can be accessed at http://investors.adaptivebiotech.com. The webcast will be archived and available for replay at least 90 days after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Forward-Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.  

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.


Use of Non-GAAP Financial Measure

To supplement our unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that we define as net loss adjusted for interest and other income, net, income tax benefit (expense), depreciation and amortization and share-based compensation expenses. We have provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.

Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.

Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect:

 

all expenditures or future requirements for capital expenditures or contractual commitments;

 

changes in our working capital needs;

 

income tax benefit (expense), which may be a necessary element of our costs and ability to operate;

 

the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;

 

the non-cash component of employee compensation expense; and

 

the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations.

In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.

ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations

201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

 


 

 

Adaptive Biotechnologies

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sequencing revenue

 

$

18,555

 

 

$

7,985

 

 

$

33,729

 

 

$

17,454

 

Development revenue

 

 

19,950

 

 

 

13,003

 

 

 

43,218

 

 

 

24,444

 

Total revenue

 

 

38,505

 

 

 

20,988

 

 

 

76,947

 

 

 

41,898

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

10,765

 

 

 

4,912

 

 

 

20,756

 

 

 

10,255

 

Research and development

 

 

37,800

 

 

 

25,992

 

 

 

71,572

 

 

 

49,927

 

Sales and marketing

 

 

23,216

 

 

 

14,332

 

 

 

43,820

 

 

 

28,339

 

General and administrative

 

 

16,066

 

 

 

12,238

 

 

 

31,002

 

 

 

24,059

 

Amortization of intangible assets

 

 

423

 

 

 

423

 

 

 

842

 

 

 

847

 

Total operating expenses

 

 

88,270

 

 

 

57,897

 

 

 

167,992

 

 

 

113,427

 

Loss from operations

 

 

(49,765

)

 

 

(36,909

)

 

 

(91,045

)

 

 

(71,529

)

Interest and other income, net

 

 

464

 

 

 

1,893

 

 

 

1,102

 

 

 

4,787

 

Income tax benefit

 

 

 

 

 

1,481

 

 

 

 

 

 

1,804

 

Net loss

 

$

(49,301

)

 

$

(33,535

)

 

$

(89,943

)

 

$

(64,938

)

Net loss per share attributable to common shareholders, basic and diluted

 

$

(0.35

)

 

$

(0.26

)

 

$

(0.64

)

 

$

(0.51

)

Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted

 

 

140,359,317

 

 

 

127,383,582

 

 

 

139,667,380

 

 

 

126,720,986

 


 

Adaptive Biotechnologies

Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)

 

 

 

June 30, 2021

 

 

December 31, 2020

 

 

 

(unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

184,186

 

 

$

123,436

 

Short-term marketable securities (amortized cost of $413,965 and $564,036, respectively)

 

 

414,227

 

 

 

564,833

 

Accounts receivable, net

 

 

14,174

 

 

 

10,047

 

Inventory

 

 

18,612

 

 

 

14,063

 

Prepaid expenses and other current assets

 

 

12,530

 

 

 

14,535

 

Total current assets

 

 

643,729

 

 

 

726,914

 

Long-term assets

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

75,235

 

 

 

39,692

 

Operating lease right-of-use assets

 

 

92,067

 

 

 

99,350

 

Long-term marketable securities (amortized cost of $91,177 and $118,429, respectively)

 

 

91,131

 

 

 

118,525

 

Restricted cash

 

 

2,138

 

 

 

2,138

 

Intangible assets, net

 

 

9,383

 

 

 

10,225

 

Goodwill

 

 

118,972

 

 

 

118,972

 

Other assets

 

 

719

 

 

 

598

 

Total assets

 

$

1,033,374

 

 

$

1,116,414

 

Liabilities and shareholders’ equity

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

6,093

 

 

$

3,237

 

Accrued liabilities

 

 

13,539

 

 

 

13,162

 

Accrued compensation and benefits

 

 

8,630

 

 

 

11,950

 

Current portion of operating lease liabilities

 

 

4,833

 

 

 

3,529

 

Current portion of deferred revenue

 

 

83,553

 

 

 

73,319

 

Total current liabilities

 

 

116,648

 

 

 

105,197

 

Long-term liabilities

 

 

 

 

 

 

 

 

Operating lease liabilities, less current portion

 

 

103,774

 

 

 

104,333

 

Deferred revenue, less current portion

 

 

119,642

 

 

 

163,618

 

Total liabilities

 

 

340,064

 

 

 

373,148

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Shareholders’ equity

 

 

 

 

 

 

 

 

Preferred stock: $0.0001 par value, 10,000,000 shares authorized at June 30, 2021 and December 31, 2020; no shares issued and outstanding at June 30, 2021 and December 31, 2020

 

 

 

 

 

 

Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2021 and December 31, 2020; 140,663,755 and 137,646,896 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively

 

 

14

 

 

 

14

 

Additional paid-in capital

 

 

1,294,506

 

 

 

1,253,971

 

Accumulated other comprehensive gain

 

 

216

 

 

 

893

 

Accumulated deficit

 

 

(601,555

)

 

 

(511,612

)

Total Adaptive Biotechnologies Corporation shareholders’ equity

 

 

693,181

 

 

 

743,266

 

Noncontrolling interest

 

 

129

 

 

 

 

Total shareholders’ equity

 

 

693,310

 

 

 

743,266

 

Total liabilities and shareholders’ equity

 

$

1,033,374

 

 

$

1,116,414

 


 

Adjusted EBITDA

The following table sets forth a reconciliation between our Adjusted EBITDA and our net loss, the most directly comparable GAAP financial measure, for each of the periods presented (in thousands, unaudited):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net loss

 

$

(49,301

)

 

$

(33,535

)

 

$

(89,943

)

 

$

(64,938

)

Interest and other income, net

 

 

(464

)

 

 

(1,893

)

 

 

(1,102

)

 

 

(4,787

)

Income tax benefit

 

 

 

 

 

(1,481

)

 

 

 

 

 

(1,804

)

Depreciation and amortization expense

 

 

2,905

 

 

 

1,998

 

 

 

5,576

 

 

 

3,976

 

Share-based compensation expense

 

 

11,249

 

 

 

6,373

 

 

 

19,733

 

 

 

11,048

 

Adjusted EBITDA

 

$

(35,611

)

 

$

(28,538

)

 

$

(65,736

)

 

$

(56,505

)

 

 

 

GRAPHIC 3 g0esetlmui4y000001.jpg GRAPHIC begin 644 g0esetlmui4y000001.jpg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end EX-101.SCH 4 adpt-20210804.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 adpt-20210804_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 adpt-20210804_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 adpt-8k_20210804_htm.xml IDEA: XBRL DOCUMENT 0001478320 2021-08-04 2021-08-04 false 0001478320 8-K 2021-08-04 ADAPTIVE BIOTECHNOLOGIES CORPORATION WA 001-38957 27-0907024 1551 Eastlake Avenue East Suite 200 Seattle WA 98102 206 659-0067 false false false false Common stock, par value $0.0001 per share ADPT NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 04, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 04, 2021
Entity Registrant Name ADAPTIVE BIOTECHNOLOGIES CORPORATION
Entity Central Index Key 0001478320
Entity Incorporation, State or Country Code WA
Entity File Number 001-38957
Entity Tax Identification Number 27-0907024
Entity Address, Address Line One 1551 Eastlake Avenue East
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98102
City Area Code 206
Local Phone Number 659-0067
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ADPT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

7X%'?GMY21R6NX8>F:G]SZ M-@@]^O,[_QO&5%D]/QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R M5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :# M7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T% M8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE M+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 M Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2S MP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DM MC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D M7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$ MKQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3 M\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ \($$4Y>*NQS $P( L !? M3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2 M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R M!F_236P@R*2*Y U+2X3[+O,&@EXN1:T/9=1,92L88!.R M'<(Y_A^[<#K3P&]'@!6^AC(, M=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,S MQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 >"CVN M*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94; M4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$% @ \($$4R0>FZ*M M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V M\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\ M_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!: M(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( /"!!%-E MD'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E M6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#H MG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4S MM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"* MJX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ M R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L M^T%.6X.^D&PO=&AE;64O M=&AE;64Q+GAM;%!+ 0(4 Q0 ( /"!!%-8V!:-9@0 1 8 M " @0X( !X;"]W;W)K&PO&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #P@01399!YDAD! #/ P $P M @ ' $@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) + #X" *% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports adpt-8k_20210804.htm adpt-20210804.xsd adpt-20210804_lab.xml adpt-20210804_pre.xml adpt-ex991_6.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "adpt-8k_20210804.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "adpt-8k_20210804.htm" ] }, "labelLink": { "local": [ "adpt-20210804_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "adpt-20210804_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "adpt-20210804.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "adpt", "nsuri": "http://www.adaptivebiotech.com/20210804", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-8k_20210804.htm", "contextRef": "C_0001478320_20210804_20210804", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "adpt-8k_20210804.htm", "contextRef": "C_0001478320_20210804_20210804", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.adaptivebiotech.com/20210804/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-21-040826-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-040826-xbrl.zip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end